Lebrikizumab Patients Treated in the Real World: First North American data from the PPDTM CorEvitasTM AD Registry

Main Article Content

Eric Simpson
Oregon Health and Science University, Portland, Oregon, USA

Vimal H. Prajapati
University of Calgary, Alberta, Canada; Skin Health & Wellness Centre, Calgary, Alberta, Canada; Dermatology Research Institute, Calgary, Alberta, Canada; Probity Medical Research, Calgary, Alberta, Canada

William A. McCann
Allergy Partners, Asheville, North Carolina, USA

Dr Zach Dawson
Eli Lilly and Company, Indianapolis, Indiana, USA

Evangeline Pierce
Eli Lilly and Company, Indianapolis, Indiana, USA

Alvin H. Li
Thermo Fisher Scientific, Waltham, Massachusetts, USA

C. Jean Choi
Thermo Fisher Scientific, Waltham, Massachusetts, USA

Jonathan I. Silverberg
George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Keywords

atopic dermatitis, lebrikizumab, real-world evidence

References

N/A

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/gmn1ta26

Article Details

How to Cite
1.
Lebrikizumab Patients Treated in the Real World: First North American data from the PPDTM CorEvitasTM AD Registry. J of Skin. 2025;9(6):s609. doi:10.25251/gmn1ta26
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Poster Presentations from FC25 Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>